Abstract Leflunomide can have adverse effects, but cases of subacute cutaneous lupus have more rarely been described. This drug, through its immunomodulatory effect, can favor the appearance of a Th2 lymphocyte immune response inducing lupus. A recent study has suggested that Jessner-Kanof disease (JKD) could be a dermal form of lupus. We report a case of subacute cutaneous lupus induced by leflunomide with anti-Ro/SSA Ab and unusual histological presentation, identical to that of JKD. Leflunomide can induce cutaneous lupus characterized by exclusively dermal involvement and histologically comparable to JKD. This observation therefore suggests that JKD could be a dermal variant of lupus. This prompted a revision of the classification of cutaneous lupus, which has until now been divided into acute, subacute and chronic forms but could equally be classed as epidermal, dermal and hypodermal. The last point of interest in our observation is the efficacy of a combination of chloroquine and anakinra, which led to complete remission of the articular and cutaneous symptoms after the failure of corticotherapy.
Introduction
Ms T., 56 years, was followed for seropositive rheumatoid arthritis (RA) with rheumatoid factors (RF) and anti-CCP antibodies (Ab) discovered in 2002. She had received corticotherapy together with injectable gold salts until 2003, followed by methotrexate in 2004, which was replaced on account of its inefficacy by leflunomide (20 mg/day). Three weeks after the initiation of this treatment, the patient developed a maculopapular cutaneous eruption associated with annular lesions of the face (Fig. 1a) extending to the thorax (Fig. 1b) and then the limbs. Biological tests showed a CRP level of 11.5 mg/L without anomalies of blood profile and negative HCV and HBV serology. The immunological profile revealed the presence of anti-nuclear antibodies (ANA) (1/320 with a speckled appearance) of specificity anti-Ro/SSA, which had not been detected in several previous series of blood tests. There were no anti-native DNA, anti-cardiolipid or anti-b2GPI Ab. A search for cryoglobulin was negative and there was no monoclonal immunoglobulin.
The diagnosis of subacute cutaneous lupus (SCL) was retained on account of the characteristic clinical manifestations and the occurrence of anti-Ro/SSA Ab. However, the histological presentation was that of Jessner-Kanoff disease (JKD). A cutaneous biopsy of a thoracic lesion revealed a chronic perivascular lymphocytic infiltrate in the dermis without involvement of the epidermis (Fig. 2) , while immunofluorescence (IF) showed IgG deposits on the dermal papillae. The delay in the appearance of these lesions with respect to the introduction of leflunomide pointed to an inductive role of the latter.
Discontinuation of leflunomide (without washout) and corticotherapy (20 mg/day) resulted in no significant improvement in the cutaneous lesions. Conversely, introduction of chloroquine (200 mg/day) combined with an antagonist of the interleukin-1 receptor (Ra Il-1) (anakinra) led to complete disappearance of the cutaneous and articular symptoms in 2 months.
Discussion
Leflunomide is used to treat lupus, in particular the articular manifestations [1] . This molecule can nevertheless have adverse effects, among which the most frequent are alopecia, digestive complaints, buccal ulceration and toxidermia. More rarely, cases of SCL have been described, to date in five patients suffering from RA or Sjögren's syndrome [2] [3] [4] [5] (Table 1) . Recently, in an open-label pilot study including 15 primary Sjögren's syndrome treated with leflunomide (20 mg/d), 30% of the patients had developed lupus-like skin lesions [6] .
Cases of SCL induced by drugs have also been reported for thiazides and calcium inhibitors [4] . The mechanism may differ depending on the drug. Leflunomide, through its immunomodulatory effect, can favor the appearance of a Th2 lymphocyte immune response, potentially capable of inducing lupus. However, all known cases of lupus induced by leflunomide are related to reports of SCL, without any precise explanation for this cutaneous tropism.
In our patient, the histological presentation was unusual and identical to that of Jessner-Kanof disease (JKD). On the other hand, the lesions were characterized by a dermal infiltrate without involvement of the epidermis, as is observed in SCL. A recent study has suggested that JKD could be a dermal form of lupus [7] . Among 210 cases of histologically confirmed JKD, 7.6% of the patients had systemic or cutaneous lupus, either known or appearing concomitantly with or after the diagnosis of JKD. This prompted a revision of the classification of cutaneous lupus, which has until now been divided into acute, subacute and chronic forms, but could equally be classed as epidermal, dermal and hypodermal [7] ( Table 2 ).
In conclusion, leflunomide can induce cutaneous lupus with anti-Ro/SSA Ab characterized by exclusively dermal involvement and histologically comparable to JKD. This observation therefore suggests that JKD could be a dermal variant of lupus. The last point of interest in our observation is the efficacy of a combination of chloroquine and anakinra, which led to complete remission of the articular and cutaneous symptoms after the failure of corticotherapy. Table 2 The cutaneous lesions of lupus (7) Dermo-epidermal lupus (interfacial dermatitis) 
